YAYumiko Akamine

Yumiko Akamine

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yumiko Akamine has a total of 42 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Drug Interaction Between Erlotinib and Itraconazole in a Patient With Non–Small Cell Lung Cancer

    by Hayato Yokota, Satoshi Goshima, Yuji Okuda, Sho Sakamoto, Masahide Takeda, Kazuhiro Sato, Yumiko Akamine, Katsutoshi Nakayama, Masatomo Miura

    Introduction: Erlotinib (ERL) is metabolized primarily by cytochrome P450 (CYP) 3A4. We report a case of non–small cell lung cancer in which plasma ERL concentrations increased following coadministration of itraconazole (ITCZ). Case Presentation: In this patient, a 67‐year‐old man receiving ERL 150 mg/day, the trough plasma concentration ( C 0 ) of ERL and its major metabolite, O‐desmethyl ERL (OSI‐420), increased following coadministration of ITCZ. The total clearance of ERL at steady state was 6.1 L/h. The mean C 0 of ERL and OSI‐420 were 437 and 47.1 ng/mL, respectively, and the C 0 ratio of OSI‐420/ERL was 0.108. With coadministration of oral ITCZ (200 mg/day capsule), the mean C 0 of ERL and OSI‐420 increased to 1124 and 166 ng/mL, respectively, and the mean C 0 ratio of OSI‐420/ERL increased to 0.147. The mean C 0 of ITCZ and the sum of ITCZ and the active metabolite hydroxyitraconazole (OH‐ITCZ) were 109 and 271 ng/mL, respectively. The mean C 0 of ERL increased approximately 2.5‐fold. Conclusion: Even at the relatively lower C 0 of ITCZ (compared with the recommended target value), ITCZ coadministration increased the C 0 of ERL. In patients with a sufficient ERL C 0 of more than 500 ng/mL prior to ITCZ coadministration or patients exhibiting adequate absorption of oral ITCZ, the risk of ERL‐related adverse events with ITCZ coadministration may increase due to further elevation of the ERL C 0 . Therefore, when ERL is coadministered with ITCZ, careful monitoring for adverse effects and appropriate dose adjustments are required, considering potential changes in ERL concentrations. Management using the C 0 of ERL and ITCZ may be necessary.

  • Tacrolimus concentrations after renal transplantation in a mother‐neonate dyad: Maternal, neonatal and breast milk measurements

    by Yumiko Akamine, Nobuhiro Fujiyama, Hideaki Kagaya, Mitsuru Saito, Hiroshi Miura, Yukihiro Terada, Tsutomu Takahashi, Shigeru Satoh, Masatomo Miura

    What is known and objective We aim to add to the few reports on tacrolimus concentrations in breast milk and in maternal, umbilical vein and neonatal blood after maternal renal transplantation. Case summary In a 30-year-old pregnant woman, the tacrolimus concentration at delivery was the same in maternal, umbilical vein and neonatal blood. The breast milk/maternal blood tacrolimus ratio ranged from 0.40 to 0.64. What is new and conclusion The maternal and neonatal blood tacrolimus concentrations at birth are equivalent; thus, one must assume that maternal tacrolimus concentrations directly affect the foetus and/or neonate. Tacrolimus is not detectable in the neonate 3 weeks after birth, suggesting that there is minimal transfer through breast milk.


  • Open Access

    Effects on monotherapy and reduction of antipsychotic drugs by clozapine therapy in Japanese patients with treatment‐resistant schizophrenia

    by Yumiko Akamine, Yuka Kikuchi, Masatomo Miura

    What is known and objective The schizophrenia guidelines in Japan and many other countries describe clozapine as the first‐choice drug for patients with treatment‐resistant schizophrenia. However, there have been no reports to date on the effects of the introduction of clozapine on the prescription of other antipsychotics and concomitant drugs. Methods In this study, we retrospectively investigated the prescription of antipsychotics and concomitant drugs before vs 6 months after and 12 months after switching to clozapine. Results and discussion Clozapine was introduced to 62 patients with treatment‐resistant schizophrenia, and 51 patients continued on clozapine therapy. Six months after switching to clozapine, there was a significant decrease in the mean number of antipsychotic drugs (2.04 ± 0.75 vs 1.10 ± 0.30: p < 0.001) and in the mean chlorpromazine equivalent value (1024 ± 73 mg/day vs 781 ± 391 mg/day: p < 0.001) compared to before switching. Moreover, antipsychotic monotherapy increased from 24% to 90% after switching to clozapine. In addition, the number of concomitant benzodiazepines, anti‐parkinson drugs and antidepressants also significantly decreased 6 and 12 months after switching to clozapine (p < 0.001 for benzodiazepines and anti‐parkinson drugs, and p < 0.05 for antidepressants). What is new and conclusion Our study suggests that switching to clozapine may reduce the use of antipsychotic combination therapy, and may also reduce the number of concomitant drugs.


  • Effects of proprotein convertase subtilisin/kexin type 9 and nilotinib plasma concentrations on nilotinib‐induced hypercholesterolaemia in patients with chronic myeloid leukaemia

    by Maiko Abumiya, Yumiko Akamine, Shiori Sato, Saori Takahashi, Tomoko Yoshioka, Yoshihiro Kameoka, Naoto Takahashi, Masatomo Miura

    What is known and objective The purpose of this study was to investigate the relationships among nilotinib plasma trough concentration (C0), low‐density lipoprotein (LDL) cholesterol, and PCSK9 plasma concentration in 31 patients with chronic myeloid leukaemia. Methods Plasma concentrations of nilotinib and PCSK9 were measured by high‐performance liquid chromatography and enzyme‐linked immunosorbent assays, respectively. Results and discussion LDL cholesterol concentrations at 1 month after nilotinib treatment were significantly increased compared with those before therapy. The mean C0 (±SD) of nilotinib at 1, 2, and 3 months after nilotinib treatment were 645 ± 516, 902 ± 623, and 951 ± 1088 ng/mL, respectively. Mean PCSK9 concentrations at 3 months after nilotinib treatment were significantly higher than those at the start of therapy (320 vs 257 ng/mL, respectively, P = .019). When the change rate in the PCSK9 concentration induced by nilotinib was classified with a cut‐off value of +40%, the change rate in LDL cholesterol in patients with a change rate in PCSK9 of ≥40% was significantly higher than that in patients with a PCSK9 change rate of P = .043); however, there were no differences in mean nilotinib C0. What is new and conclusion Nilotinib may lead to hypercholesterolaemia by increasing plasma concentrations of PCSK9 after indirect inhibition of mammalian target of rapamycin (mTOR) complex 1. In addition, certain patients seem to have high sensitivity for nilotinib in a signalling cascade of the PI3K/Akt/mTOR pathway, despite low plasma concentrations of nilotinib. Consequently, nilotinib‐induced hypercholesterolaemia could not be predicted based on the plasma concentration of nilotinib.


  • Drug interactions between warfarin and lenvatinib in a patient with the CYP2C9 * 1/*3 and VKORC1 ‐1639G/A genotype

    by Hironobu Yagishita, Shinichiro Minami, Yumiko Akamine, Shotaro Kato, Katsunori Iijima, Masatomo Miura

    What is known and objective Lenvatinib inhibits CYP2C8. (S)‐Warfarin is metabolized to (S)‐7‐hydroxywarfarin by CYP2C9 and (S)‐4'‐hydroxywarfarin by CYP2C8. Here, we report drug interactions between warfarin and lenvatinib in a patient with CYP2C9*1/*3. Case summary The patient was administered warfarin. His international normalized ratio (INR) was 1.92 before lenvatinib administration. On day 8 after beginning 12 mg/day lenvatinib, plasma trough concentrations of lenvatinib and (S)‐warfarin were 33.3 ng/mL and 0.67 μg/mL, respectively. On day 10, his INR increased to 3.48. What is new and conclusion Lenvatinib‐dependent (S)‐warfarin inhibition could involve CYP2C9 and CYP2C8. After initiating warfarin plus lenvatinib, INR assays are necessary.


  • Comparison of electrochemiluminescence immunoassay and latex agglutination turbidimetric immunoassay for evaluation of everolimus blood concentrations in renal transplant patients

    by Y. Akamine, H. Kagaya, T. Ohkubo, S. Satoh, M. Miura

    What is known and objective For analysis of blood concentrations of everolimus, many hospital laboratories use either latex agglutination turbidimetric immunoassay (LTIA) or electrochemiluminescence immunoassay (ECLIA). However, no studies have compared both immunoassay methods under the same conditions. Accordingly, in this study, we compared everolimus blood concentrations obtained by LTIA and ECLIA in renal transplant patients. Methods Blood samples (n = 230) from 60 renal transplant patients (19 female and 41 male) were evaluated using both immunoassays. Subsequently, we switched the assay for detection of everolimus blood concentrations from LTIA to ECLIA as a clinical application. Three quality control (QC) samples for LTIA were analysed using ECLIA, and 3 QC samples for ECLIA were analysed using LTIA. Results The Deming regression of ECLIA versus LTIA generated the following parameters: slope, 1.0067 and intercept, 1.7489 ng/mL, in the analysis of 230 samples. Bland‐Altman analysis showed an average positive bias of 1.73 ng/mL between ECLIA and LTIA. When the clinical apparatus was switched from LTIA to ECLIA, the average everolimus blood concentration assayed by LTIA before switching was 3.57 ng/mL, whereas that by ECLIA after switching in the same patients taking the same daily dose (mean: 1.43 mg/day) was 5.85 ng/mL. The QCs assayed using LTIA were lower by an average of 67.3% (range: 55.8%‐79.5%) for ECLIA, and in the same 230 samples from patients, the everolimus blood concentrations assayed by LTIA were lower by an average of 67.4% (range: 37.1%‐114.5%) of ECLIA. What is new and conclusion Analysis of everolimus concentrations by immunoassays with high precision and accuracy is required to ensure long‐term survival of transplant recipients. Although the concentrations of QCs and calibrators of everolimus in LTIA were previously corrected to 70% concentration because of cross‐reactivity with everolimus metabolites, these adjustments may need to be reviewed.


  • An update on the clinical pharmacokinetics of fexofenadine enantiomers

    by Yumiko Akamine, Masatomo Miura

    Introduction: Fexofenadine is administered as a racemic mixture of (R)- and (S)-enantiomers. The plasma concentrations of (R)-fexofenadine in humans are about 1.5-fold higher than those of the (S)-enantiomer. Such differences in the pharmacokinetics between fexofenadine enantiomers are likely to be dependent on stereoselectivity for affinity to drug-transporters. Areas covered: This review focuses on elucidation of differences in clinical pharmacokinetics between fexofenadine enantiomers. Expert opinion: Differences in pharmacokinetics between fexofenadine enantiomers were caused by organic anion transporting polypeptide (OATP) 2B1, with a minor contribution from P-glycoprotein (P-gp). In vitro studies using OATP2B1 cRNA showed that (R)-fexofenadine uptake into oocytes is greater than (S)-enantiomer uptake. P-gp inducers, carbamazepine, and inhibitors such as itraconazole and verapamil show greater effects on the pharmacokinetics of (S)-fexofenadine. Apple juice and grape fruit juice, OATP2B1 inhibitors, significantly decrease the exposure of both fexofenadine enantiomers, particularly the (S)-enantiomer, but do not change the t1/2. Rifampicin significantly increases plasma concentrations of both enantiomers through inhibition of OATP1B3, whereas enantioselectivity of fexofenadine uptake by OATP1B3-expressing cells has not been observed. Combinations of multiple transporters such as OATP2B1 and P-gp facilitate enantioselective disposition of fexofenadine. Drug-transporters appear to be capable of chiral discrimination for transport of drugs with an asymmetric center.


  • A comparison of the effects ofCYP3A5polymorphism on tacrolimus blood concentrations measured by 4 immunoassay methods in renal transplant patients

    by Yumiko Akamine, Hideaki Kagaya, Tadashi Ohkubo, Shigeru Satoh, Masatomo Miura

    The anti-tacrolimus antibodies used in commercial immunoassay methods have cross-reactivity with tacrolimus metabolites. The aim of this study was to investigate differences in the effects of CYP3A5 polymorphism on tacrolimus concentrations obtained by four immunoassay methods in renal transplant patients. Samples (n = 508) were evaluated using four immunoassays (chemiluminescence enzyme immunoassay [CLIA], affinity column-mediated immunoassay [ACMIA], electrochemiluminescence immunoassay [ECLIA] and latex agglutination turbidimetric immunoassay [LTIA]). Bland-Altman plots showed average biases of −0.12 (±1.96 SD: −1.30-1.05) ng/mL for CLIA, −0.30 (−1.59-1.00) ng/mL for ECLIA, 0.42 (−1.21-2.05) ng/mL for ACMIA and 1.88 (−0.51-4.28) ng/mL for LTIA, when considering the mean of the three immunoassays (CLIA, ECLIA and ACMIA). In multiple regression analysis, the difference (CLIA—mean) was affected by haematocrit levels. Differences in ECLIA were correlated with red blood cell counts. For LTIA, CYP3A5 genotype and haematocrit levels were identified as independent predictors for this bias. The results obtained by CLIA, ECLIA and ACMIA were not affected by CYP3A5 polymorphism. However, in LTIA, CYP3A5*1/*3-derived data exhibited an inverse relationship in Bland-Altman analysis (slope: −0.0824). Higher cross-reactivity with 12-hydroxy tacrolimus at lower concentrations may occur in patients with the CYP3A5*1/*3 genotype. Because patients with the CYP3A5*1 allele identified using LTIA may show higher blood concentrations of tacrolimus at lower target concentrations, for example 3.0 ng/mL, compared with other immunoassay methods, there is a need for sufficient consideration of the interpretation of values measured by LTIA.


  • Open Access

    Effects of multiple-dose rifampicin 450 mg on the pharmacokinetics of fexofenadine enantiomers in Japanese volunteers

    by Y. Akamine, M. Miura, N. Yasui-Furukori, I. Ieiri, T. Uno

    Rifampicin is a potent inducer of P-glycoprotein (P-gp) and inhibitor of organic anion-transporting polypeptides (OATPs), with fexofenadine acting as a substrate for both mechanisms. Simultaneous administration of single- or multiple-dose rifampicin 600 mg significantly increases the concentrations of fexofenadine enantiomers by inhibiting OATP transporters. However, the effects of rifampicin 450 mg are unknown. Here, we evaluated the effects of multiple doses of rifampicin 450 mg on the pharmacokinetics of fexofenadine enantiomers in healthy Japanese volunteers. In this randomized, two-phase, double-blind crossover study, 10 healthy volunteers received rifampicin 450 mg/day or placebo for 7 days. On day 7, fexofenadine 60 mg was co-administered simultaneously. Rifampicin significantly increased the mean area under the plasma concentration-time curve (AUC) of (R)- and (S)-fexofenadine (3.10-fold and 3.48-fold, respectively) and decreased the renal clearance of (R)- and (S)-fexofenadine (0.40-fold and 0.47-fold, respectively), causing marked differences in the mean amounts of these enantiomers excreted into the urine in the rifampicin phase (P < 0.001). These results indicated that multiple doses of rifampicin 450 mg may be sufficient to inhibit the renal influx transporter and OATP-mediated hepatic uptake of both enantiomers. Moreover, these effects may be greater than the P-gp-inductive effects of rifampicin. Therefore, the interactive mechanism of multidose rifampicin may occur through a combination of OATP and P-gp transporters, thereby altering the pharmacokinetics of fexofenadine enantiomers. In this study of rifampicin 450 mg, the interactive magnitude of the mean AUC values of fexofenadine enantiomers was higher than that observed in the previous study of rifampicin 600 mg, and no dose-dependent inhibitory effects of rifampicin were observed. These effects may be clinically significant in patients receiving fexofenadine and rifampicin.